Clinical Trial Search

Primary: Percent Change From Baseline in Surface-to-Curve Ratio (SCR) in the Distal Radius at Month 18 Endpoint — 4.53 percent (%) change of ratio — p=0.363

Primary: Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12 — 12.5; 16.3 percent risk — p=<0.001

Primary: Defocus Curve — 0.585; 0.653; 0.490; 0.475 LogMAR

Primary: Binocular Visual Acuity at Distance, Near and Intermediate — 0.00; 0.13; 0.07; 0.00 LogMAR

Primary: Expert Panel Overall Assessment Following 2 Years on Drug — 34; 33; 81; 86 Participants

Primary: Change From Baseline to 12-Week Endpoint in the Brief Pain Inventory (BPI) "24-Hour Average Pain" Item (Question 3) of the BPI-Modified Short Form Score — -2.04; -1.70…

Primary: Total Number of Asthma Exacerbations Reported During the Treatment Period — 24; 25 Number of asthma exacerbations — p=0.928

Primary: Percent of Participants Who Survived Without AIDS Progression. — 13; 16 percent of participants — p=0.45

Primary: Average Daily Pain Score Box Scale-11 (BS-11) Recorded at Week 12 (Average Pain Over Last 24 Hours) — 4.2; 4.64 Units on a BS-11 scale at Week 12 — p=0.002

Primary: Change From Baseline in Inflammatory Lesion Counts (Papules,Pustules, and Nodules) at Week 12 — 38.94; 40.78; -25.77; -24.82 Number of Lesions

Primary: Change From Baseline in Inflammatory Lesion Counts (Papules, Pustules and Nodules) at Week 12 — 38.96; 40.06; -24.05; -25.82 Number of Lesions

Primary: The Percentage of Patients Reaching at Least a 30% Reduction in PTH and/or Values in Range 150-300 pg/mL — 96.6 Percentage of participants

Primary: Change From Baseline in Mean Conjunctival Hyperemia Scores at Month 3 — 0.74; 0.86; 0.74; 0.05 Scores on Scale

Primary: Change of Brief Pain Inventory (BPI) Average Interference Score From Baseline to Week 12 — -1.4; -2.2 Scores on a scale — p=< 0.0001

Primary: Mean Frequency of Eye Drop Use Over 1 Week — 1.76; 1.66 Use per day